Genomic discoveries can contribute to therapeutics in several ways (Green and Guyer, 2011; Manolio, 2013): target identification; rational drug design; genetic stratification in clinical trials; genetic prediction of efficacy and toxicity; development of gene therapy; and even genetic influences on the outcome of psychological and social interventions. Here, the discussion focuses on how recent and forthcoming genetic discoveries about schizophrenia can help to identify drug targets to treat the disorder. Genetic effects on response to, and side-effects of, existing treatments are discussed elsewhere (Arranz et al, 2011; Harrison, 2014; Zhang and Malhotra, 2013).
